Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS4 | P49798 | 11/20 | 0.63 |
| ▸ | RGS8 | P57771 | 10/20 | 0.63 |
| ▸ | GSK3B | P49841 | 10/20 | 0.57 |
| ▸ | GSK3A | P49840 | 5/20 | 0.57 |
| ▸ | PRKCA | P17252 | 2/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.48 |
| ▸ | RGS16 | O15492 | 1/20 | 0.40 |
| ▸ | RGS19 | P49795 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23757714 | 0.92 | RGS4 (0.76) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL23757947 | 0.90 | RGS4 (0.70) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL23763661 | 0.88 | RGS4 (0.73) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL23757709 | 0.87 | GSK3B (0.56) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL23763654 | 0.87 | RGS4 (0.57) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL23757991 | 0.85 | GSK3B (0.55) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL23763500 | 0.85 | GSK3B (0.77) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL23763503 | 0.84 | RGS4 (0.58) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL23757553 | 0.83 | RGS4 (0.56) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL23763655 | 0.78 | GSK3B (0.51) | RGS4RGS8GSK3BGSK3APRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125667-A1 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | US GOV VETERANS AFFAIRS (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125667-A1 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | BRCA1, MTPN, MUSK | RGS4 2498/4885RGS8 2630/4885GSK3B 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.